| Modulation of the immune system
as an approach to attack cancer has been explored
for the past 50 years. Efficacy of this treatment
has been achieved in a limited number of
patients. However, a major obstacle of immune
therapy is the toxicity related to the
nonspecific nature of immune activation. Efforts
to improve the specificity of the immune response
have been investigated through the use of gene
therapy. Clinical trials involving gene therapy
for melanoma, lung cancer, and head and neck
cancer have been conducted by US Oncology at the
Mary Crowley Medical Research CenterBaylor
University Medical Center. These studies
represent one of the most active gene therapy
programs in the USA. Preliminary results have
helped define the mechanism of action, safety,
and potential efficacy of immune stimulatory
treatment approaches in oncology. |
nterpositional
grafting materials are often used to fill in bone gaps
that result from corrective jaw surgery and craniofacial
reconstruction. Various materials and autogenous bone
grafts from different harvest sites have been advocated
to maintain the repositioned structures. Each of these
choices has inherent drawbacks. Porous block
hydroxyapatite (PBHA) has provided an alternative to bone
grafting in these procedures. PBHA has parallel channels
of 230 ? in diameter, with interconnecting fenestrations
between the channels of 190 ? in diameter. This pore
size is not only similar to normal osteon size in bone
(190 ?), but it also conforms to research findings of
150 to 200 ? as optimal for bone ingrowth. PBHA
functions as an osteoconductive matrix when placed
against or between bone structures, allowing bone and
soft tissue ingrowth through it. The use of rigid
fixation is necessary for stress protection of the PBHA
grafts and the elimination of micromovement to enhance
bone growth through the grafts. The clinical,
radiographic, and histological studies of PBHA used as a
bone graft substitute in corrective jaw surgery,
craniofacial surgery, and facial augmentation have
demonstrated the efficacy of this material for these
applications, with a low incidence of complications.
Orthognathic surgery is the surgical repositioning of
the jaw structures with osteotomies. Surgical correction
of jaw and facial deformities may require repositioning
of the upper jaw (maxilla), lower jaw (mandible), and
craniofacial structures, creating bone gaps or continuity
defects. These bone gaps can be small or quite large, as
seen in cases of maxillary or midfacial hypoplasia.
Failure to graft these gaps can result in instability,
relapse, and nonunion of the bone structures with
subsequent redevelopment or worsening of the original
deformity.
Various interpositional grafting materials have been
advocated to maintain the repositioned bony structures.
Autogenous bone grafts from the calvarium, iliac crest,
or ribs as well as freeze-dried bone and the solid block
form of hydroxyapatite have been used as interpositional
graft materials (14). Each of these materials has
inherent drawbacks. Autologous bone requires a secondary
surgical harvest site, with its inherent morbidity, and
the bone may undergo resorption and remodeling during
healing, which has been associated with relapse.
Freeze-dried bone undergoes significantly greater
resorption and remodeling than does autologous bone,
takes longer to heal, has a higher infection rate, and
carries the problems of an allograft. Solid block
hydroxyapatite does not allow bony ingrowth, is very
difficult to shape, does not become intimately
incorporated into the bony matrix, and requires
autologous bone grafting to facilitate healing and
stability.
Porous block hydroxyapatite (PBHA) (Interpore 200,
Interpore International, Irvine, Calif) provides an
alternative to bone grafting in corrective jaw surgery
and craniofacial surgery. PBHA material is derived from
marine coral of the genus Porities. This coral has
an average void volume of 66%. Parallel channels are 230
? in diameter, with interconnecting fenestrations
between these channels of 190 ? in diameter (5). In
1979, Holmes (6) proposed that this coral could be
processed through replamineform, converting the
calcium bicarbonate exoskeleton of the marine coral into
pure hydroxyapatite through an exothermic reaction
(710). The hydroxyapatite matrix structure thus
formed functions as a scaffold for bone and soft tissue
ingrowth (Figures 1 and 2).
With autogenous bone grafts, the normal healing
process includes the initial revascularization and
resorption of osteons. The interstitial bone remains and
serves as a stromal framework for the formation of new
bone. The residual bony matrix contains pores large
enough to permit tissue ingrowth. Because of its special
porous nature, PBHA is osteoconductive and allows
intimate bony ingrowth (5). The pore size of PBHA is not
only similar to normal osteon bone size (190 ?) but also
conforms to research that confirms a minimum pore size of
100 ?, preferably 150 to 200 ?, for optimal bone
ingrowth (611).
SURGICAL CONSIDERATIONS
The surgeon should change gloves before handling the
PBHA material because oral and nasal flora and debris
previously picked up on gloves during the pregrafting
stages of surgery could contaminate the PBHA, resulting
in a subsequent infection. Several important physical
characteristics of PBHA should be noted. In its initial
form, PBHA is brittle and must be handled and shaped
carefully so it does not inadvertently fracture, although
the material becomes very strong after healing. It is
important to use irrigation when cutting the individual
grafts from the larger blocks with a bur and when
refining the contours with a scalpel blade (Figure
3). Irrigation improves the PBHA strength,
minimizes aberrant fracture, and helps keep debris out of
the pores.
PBHA grafts can be used as interpositional (inlay)
grafts placed between osteotomies or as facial
augmentation (onlay) grafts. They can be applied to the
maxilla, mandible, chin, orbit, zygoma, nose, forehead,
and cranium. Onlay grafts may require stabilization by
placing bone screws through the material, as in PBHA chin
or cheek onlay grafts. A lag screw technique should be
used with minimal tightening to prevent fracturing of the
grafts.
The importance of rigid skeletal stabilization when
using PBHA grafts for maxillary surgery cannot be
overemphasized. Rigid fixation is paramount to provide
the necessary stability and stress protection for the
PBHA grafts to heal properly. The use of 4 bone plates is
recommended to stabilize the maxilla (Figure
4), with 2 bone screws above and 2 bone
screws below the level of osteotomy for each bone plate
(12, 13). The grafts in the maxilla are accurately
contoured and wedged in position and are not directly
fixated. If there is excessive mobility between the bone
segments and PBHA grafts or a functional overload, the
grafts could become displaced or fractured.
Alternatively, a significant decrease in the amount of
bone growth through the implants could occur, resulting
in a nonunion. A soft diet is encouraged for 3 to 4
months during the initial postsurgery healing phase to
minimize loading and micromovement, thus preventing
displacement, fracture, or nonunion of the grafts. Bone
growth through the grafts is essentially complete in 4
months.
CLINICAL AND RADIOGRAPHIC STUDIES
Wolford et al introduced the use of PBHA as a bone
graft substitute in orthognathic and craniofacial surgery
(12). This research, performed at Baylor University
Medical Center and Baylor College of Dentistry, resulted
in Food and Drug Administration approval of PBHA for
these applications. This study consisted of clinical and
radiographic evaluations of 92 consecutive patients who
received a total of 355 PBHA grafts, with 294 to the
maxilla, 41 to the mandible, and 20 to the craniofacial
region. There were 202 grafts directly exposed to the
maxillary sinus. Follow-up time ranged from 8 to 24
months and demonstrated very good results. The most
frequent complication occurred in 5 of 92 patients
(5.4%), where a midpalatal graft used to stabilize upper
jaw expansion was lost secondary to exposure of the graft
to oral or nasal flora and debris, resulting from
incisions or tears of the mucosa directly over the
implants at the time of surgery. After identifying the
causative factors, modifications in palatal and nasal
soft tissue management essentially eliminated further
occurrences of this complication.
Rosen and Ackerman reported on 46 patients who
received PBHA grafts during orthognathic surgery, with a
complication rate of 4.3% after a follow-up period of 6
to 20 months (14, 15). Moenning and Wolford reported on
49 patients, with a minimum 24-month follow-up, in whom
215 PBHA grafts had been placed during orthognathic
surgery (16). Nine patients had complications, including
4 who lost midpalatal grafts, 4 who had sinusitis treated
with antibiotics and decongestants without loss of
grafts, and 1 patient with a partially displaced
mandibular graft that remained without untoward effects.
Cottrell and Wolford clinically and radiographically
evaluated 111 patients, with an average follow-up time of
7.2 years (range, 5.0 to 10.3 years). A total of 471 PBHA
grafts were placed: 403 in the maxilla, 44 in the
mandible, and 24 in the periorbital region (17).
Twenty-three grafts (4.9%) were lost during the
evaluation period. Maxillary interpositional grafting
with direct exposure to the maxillary sinus had a 97%
success rate, with 9 (of 289) grafts lost in 3 patients.
One chin graft that was well healed was removed because
of patient dissatisfaction with the aesthetics. Seven of
50 (14%) midpalatal grafts used for maxillary expansion
were lost, primarily in the early cases, where soft
tissue incisions or tears directly over the grafts
exposed them to the oral or nasal flora and debris at the
time of surgery. When PBHA was used for alveolar cleft
grafting, there was a 100% failure rate (5 of 5).
Therefore, PBHA should not be used for this specific
application. Failure was related to the inability to
achieve a watertight soft tissue closure over the PBHA
graft, thus allowing leakage of oral flora into the
graft.
Wardrop and Wolford published a radiographic stability
study on 14 maxillary advancement cases, 11 maxillary
downgraft (vertical lengthening) cases, and 3 midfacial
advancement cases (13). All were stabilized with bone
plates and PBHA grafts, with <0.5 mm relapse in any
direction.
Castro et al recently completed a radiographic
stability study of maxillary advancement of >5 mm,
with rigid fixation and PBHA grafts (18). The average
follow-up time for the 78 patients in the study was 25.8
months. The study demonstrated that the mean horizontal
and vertical relapse was <0.5 mm in all patients,
indicating good stability. Castro et al also evaluated
the stability of maxillary downgrafting >5 mm using
rigid fixation and PBHA grafts on 43 patients, with an
average follow-up of 31.3 months (19). The results were
also stable, with an average vertical relapse of <0.6
mm.
Moenning and Wolford reported a radiographic study on
12 patients in which PBHA was used for onlay grafts
stabilized with bone screws to the anterior mandible for
chin augmentation (20). This study showed no bone
resorption, excellent stability, and radiographic
evidence of bone ingrowth into the grafts.
HISTOLOGICAL STUDIES
Holmes et al reported on 17 biopsies of PBHA grafts
used in corrective jaw surgery in 9 patients: 14 biopsies
from the maxilla and 3 from the mandible (21). Histometry
demonstrated an average composition of 48.5%
hydroxyapatite matrix, 18% bone, and 33.5% soft tissue in
PBHA grafts harvested 4.7 to 16.4 months postsurgery (Figure
5). In these biopsies, the composition of
the adjacent normal maxillary and mandibular bone
averaged 66.5% bone and 33.5% soft tissue, indicating
that the ratio of hydroxyapatite/bone to soft
tissue/vascular space is equivalent to normal bone. The
study also demonstrated that bone growth through the PBHA
grafts was essentially complete in 4 months, with further
progression of the healing process resulting in
maturation of the ingrown bone.
Nunes et al reported on the histometrics of PBHA graft
biopsies from 9 patients, harvested 14 to 30 months
postsurgery (mean, 19.1 months) (22). The mean
composition of the samples was 53% PBHA, 27% bone, and
21% soft tissue. The grafts had less soft tissue than the
adjacent bone (30% soft tissue). The grafts had bone
contact over 60% of their surfaces. A near-balance
between the PBHA grafts and surrounding bone had been
established.
Ayers et al evaluated 25 biopsies of maxillary PBHA
grafts from 17 patients (23). The grafts had been placed
into the lateral maxillary wall, juxtaposed to the
maxillary sinus during orthognathic surgery, and were
harvested 4 to 138 months postgrafting. Histometric
examination showed the mean composition of the samples
was 51% hydroxyapatite matrix, 23% bone, and 26% soft
tissue. No inflammatory responses were observed. There
was no significant difference in microhardness values
between the bone in the PBHA grafts and the adjacent
maxillary bone. Bone ingrowth appeared to plateau at
around 20 months, reaching an equilibrium in which the
relative amount of osseous tissue remained constant.
DISCUSSION
Where continuity defects exist, interpositional bone
grafting is indicated in orthognathic surgery to provide
bony continuity, improve healing, improve stability,
decrease surgical relapse, and provide surgical stability
in traditionally unfavorable jaw repositioning movements.
PBHA is essentially nonresorbing and is incorporated into
the adjacent bony structures, becoming a permanent part
of the skeleton. The use of PBHA as an alloplastic
grafting material has several advantages over other types
of grafts: no donor site morbidity is involved, PBHA and
adjacent bone are not resorbed, there is no known
hypersensitivity or immune response, the substance is
easily manipulated, there are no working time
constraints, surgical time is decreased, blood loss is
decreased, the volume is unlimited, and healing is faster
resulting in a shorter recovery time. Prior to using
rigid fixation and PBHA, maxillary downgrafting was
unstable and unpredictable, resulting in significant
relapse problems. The use of PBHA combined with rigid
internal fixation in maxillary downgraft and advancement
surgery has demonstrated long-term stability and
predictability (13, 18, 19).
Biocompatibility of hydroxyapatite has been
established, as well as the long-term retention of PBHA
used in orthognathic and craniofacial surgery (17).
Histologic studies (2123) and a long-term clinical
study (17) demonstrate good biologic acceptance of the
grafts in association with the maxillary sinus.
No complications have been reported with the
interdental PBHA grafts. Grafts are placed in osteotomy
sites between teeth roots when the maxilla is sectioned
into >=2 segments to aid in repositioning, and a bone
gap is created between the segments. However, if
orthodontics requires movement of tooth roots into the
grafted area, PBHA grafts should not be used because PBHA
will not resorb and tooth root damage is likely to occur.
Autogenous interdental bone grafting should be used in
this situation.
Postsurgical displacement or fragmentation of the PBHA
grafts can occur as a result of the following:
- Inadequate rigid fixation and stress protection
- Improper contouring or placement of the implant
into the osteotomy site
- Parafunctional habits (i.e., clenching, bruxism)
- Poor patient compliance
- Trauma
Infection can occur at any site but most often appears
to be correlated with exposure to oral or nasal flora and
debris, improper fixation, mobility of the graft,
fracture of the graft and fragment displacement, or the
presence of a presurgical infection in the area.
Parafunctional habits can contribute to mobility of
the maxilla, which will interfere with healing,
significantly decrease bone ingrowth, and possibly cause
graft fracture and/or displacement. Control of
parafunctional habits postsurgery with appropriate
medications will decrease stress on the jaws and graft
materials during the initial healing phase and thus will
enhance outcomes.
As previously mentioned, PBHA is not recommended for
alveolar cleft grafting because of a high failure rate.
Cancellous iliac bone grafting works best for alveolar
cleft grafting and has the advantage of allowing the
eruption of the teeth and orthodontic tooth movements
through the graft.
| References |
| 1. |
Araujo
A, Schendel SA, Wolford LM, Epker BN. Total
maxillary advancement with and without bone
grafting. J Oral Surg
1978;36:849358. |
| 2. |
Bloomquist
DS, Turvey TA. Bone grafting in dentofacial
deformities. In Bell WH, ed. Modern Practice
in Orthognathic and Reconstructive Surgery.
Philadelphia: WB Saunders Co, 1992. |
| 3. |
Epker
BN, Friedlaender G, Wolford LM, West RA. The use
of freeze-dried bone in middle-third face
advancements. J Oral Surg Oral Med Oral Path
1976;42:278289. |
| 4. |
Kent
JN, Zide MF, Kay JF, Jarcho M. Hydroxylapatite
blocks and particles as bone graft substitutes in
orthognathic and reconstructive surgery. J
Oral Maxillofac Surg 1986;44:597605. |
| 5. |
Wolford
LM. The use of porous block hydroxyapatite. In
Bell WH, ed. |
| 6. |
Holmes RE. Bone regeneration
within a coralline hydroxyapatite implant. Plastic
Reconstr Surg 1979;63:626633. |
| 7. |
Hanusiak WM. Polymeric
replamineform biomaterials and a new membrane
structure [doctoral thesis]. Hershey, Penn:
Pennsylvania State University, August 1977. |
| 8. |
Roy DM. Porous biomaterials
and methods of making same. US patent 3929971.
December 30, 1975. |
| 9. |
Roy DM, Linnehan SK.
Hydroxyapatite formed from coral skeletal
carbonate by hydrothermal exchange. Nature
1974;247:220222. |
| 10. |
White RA, Weber JN, White EW.
Replamineform: a new process for preparing porous
ceramic, metal, and polymer prosthetic materials.
Science 1972;176:922924. |
| 11. |
Holmes RE, Hagler HK, Coletta
CA. Thick-section histometry of porous
hydroxyapatite implants using backscattered
electron imaging. J Biomed Mater Res
1987;21:731739. |
| 12. |
Wolford LM, Wardrop RW, Hartog
JM. Coralline porous hydroxylapatite as a bone
graft substitute in orthognathic surgery. J
Oral Maxillofac Surg 1987;45:10341042. |
| 13. |
Wardrop RW, Wolford LM.
Maxillary stability following downgraft and/or
advancement procedures with stabilization using
rigid fixation and porous block hydroxyapatite
implants. J Oral Maxillofac Surg
1989;47:336342. |
| 14. |
Rosen HM. Porous, block
hydroxyapatite as an interpositional bone graft
substitute in orthognathic surgery. Plast
Reconstr Surg 1989;83:985990,
discussion 991993. |
| 15. |
Rosen HM, Ackerman JL. Porous
block hydroxyapatite in orthognathic surgery. Angle
Orthod 1991;61:185191, discussion 192. |
| 16. |
Moenning JE, Wolford LM.
Coralline porous hydroxyapatite as a bone graft
substitute in orthognathic surgery: 24-month
follow-up results. Int J Adult Orthodon
Orthognath Surg 1989;4:105117. |
| 17. |
Cottrell DA, Wolford LM.
Long-term evaluation of the use of coralline
hydroxyapatite in orthognathic surgery. J Oral
Maxillofac Surg 1998;56:935. |
| 18. |
Castro V, Freitas RZ, Wolford
LM. Stability following maxillary advancement
using rigid fixation and porous block
hydroxyapatite [abstract].
Annual Meeting of the American Association of
Oral and Maxillofacial Surgeons, Boston, Mass,
September 29October 2, 1999. |
| 19. |
Castro V, Freitas RZ, Wolford
LM. Stability of maxillary downgraft procedures
using rigid fixation and porous block
hydroxyapatite [abstract]. Annual Meeting of the
American Association of Oral and Maxillofacial
Surgeons, Boston, Mass, September 29October
2, 1999. |
| 20. |
Moenning JE, Wolford LM. Chin
augmentation with various alloplastic materials:
a comparative study. Int J Adult Orthodon
Orthognath Surg 1989;4:175187. |
| 21. |
Holmes RE, Wardrop RW, Wolford
LM. Hydroxylapatite as a bone graft substitute in
orthognathic surgery: histologic and histometric
findings. J Oral Maxillofac Surg
1988;46:661671. |
| 22. |
Nunes CR, Simske SJ, Sachdeva
R, Wolford LM. Long-term ingrowth and apposition
of porous hydroxylapatite implants. J Biomed
Mater Res 1997;36:560563. |
| 23. |
Ayers RA, Simske SJ, Nunes CR,
Wolford LM. Long-term bone ingrowth and residual
microhardness of porous block hydroxyapatite
implants in humans. J Oral Maxillofac Surg
1998;56:1297301;1302. |
| |